公开(公告)号：WO2008118356A3

公开(公告)日：2008-11-20

申请号：PCT/US2008003735

申请日：2008-03-21

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA ,  BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

Inventor： BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/13 ,  C12N15/63

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不良免疫应答的疾病。

公开(公告)号：WO2005003175A2

公开(公告)日：2005-01-13

申请号：PCT/US2004/018708

申请日：2004-06-14

Applicant: BIOGEN IDEC MA INC. ,  TAYLOR, Frederick, R. ,  BENJAMIN, Christopher, D. ,  BURKLY, Linda, C. ,  GARBER, Ellen, A.

Inventor： TAYLOR, Frederick, R. ,  BENJAMIN, Christopher, D. ,  BURKLY, Linda, C. ,  GARBER, Ellen, A.

IPC: C07K16/28

CPC classification number: C07K16/2875 ,  A61K2039/505 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76

Abstract: The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the C H2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune response with such aglycosylated anti-CD154 antibodies or antibody derivatives thereof.

Abstract translation: 本发明涉及无糖基抗CD154抗体或抗体衍生物，其特征在于在所述的Fc部分的Fc部分的CαH2区中的保守N-连接位点处进行修饰 抗体。 本发明还涉及用这种无糖基化的抗CD154抗体或其抗体衍生物治疗免疫应答相关疾病和抑制不需要的免疫应答。

公开(公告)号：WO02083854A9

公开(公告)日：2003-11-06

申请号：PCT/US0211521

申请日：2002-04-12

Applicant: BIOGEN INC ,  LYNE PAUL D ,  GARBER ELLEN A ,  SALDANHA JOSE W ,  KARPUSAS MICHAEL

Inventor： LYNE PAUL D ,  GARBER ELLEN A ,  SALDANHA JOSE W ,  KARPUSAS MICHAEL

IPC: G01N33/50 ,  A61K39/395 ,  A61K49/16 ,  A61P29/00 ,  A61P37/00 ,  C07H21/04 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28 ,  C07K16/46 ,  C12N20060101 ,  C12N1/00 ,  C12N5/10 ,  C12N5/12 ,  C12N5/20 ,  C12N5/22 ,  C12N9/00 ,  C12N15/07 ,  C12N15/09 ,  C12N15/11 ,  C12N15/13 ,  G01N33/15 ,  G01N33/53 ,  G01N33/543 ,  G01N33/567 ,  G01N33/577 ,  G06F17/00 ,  G06F17/30 ,  H04N9/64 ,  H04N13/02 ,  H04N15/00 ,  C12N

CPC classification number: C07K16/2842 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  Y02A90/26

Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.

Abstract translation: 特异性结合VLA-1整联蛋白的抗体以及使用这些抗体治疗受试者的免疫学障碍的方法。 还包括由VLA-1抗体及其配体形成的复合物的晶体结构，以及通过使用这些结构的结构坐标鉴定的VLA-1拮抗剂和激动剂。

公开(公告)号：WO9928876A3

公开(公告)日：1999-09-23

申请号：PCT/US9825585

申请日：1998-12-03

Applicant: BIOGEN INC ,  PEPINSKY R BLAKE ,  ZENG CHENHUI ,  BAKER DARREN P ,  WEN DINGYI ,  WILLIAMS KEVIN P ,  GARBER ELLEN A ,  STRAUCH KATHRYN L ,  TAYLOR FREDERICK R ,  WEINREB PAUL H ,  PETTER RUSSELL C ,  GALDES ALPHONSE

Inventor： PEPINSKY R BLAKE ,  ZENG CHENHUI ,  BAKER DARREN P ,  WEN DINGYI ,  WILLIAMS KEVIN P ,  GARBER ELLEN A ,  STRAUCH KATHRYN L ,  TAYLOR FREDERICK R ,  WEINREB PAUL H ,  PETTER RUSSELL C ,  GALDES ALPHONSE

IPC: A61K38/00 ,  C07K14/46 ,  C07K14/435 ,  A61K38/18

CPC classification number: C07K14/46 ,  A61K38/00 ,  C07K2319/00

Abstract: Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.

公开(公告)号：WO2007089601A9

公开(公告)日：2008-12-18

申请号：PCT/US2007002199

申请日：2007-01-26

Applicant: BIOGEN IDEC INC ,  LEE DANIEL H S ,  WEN DINGYI ,  PEPINSKY R BLAKE ,  RELTON JANE K ,  WANG XINZHONG ,  LUGOVSKOY ALEXEY ,  MEIER WERNER ,  GARBER ELLEN A ,  SILVIAN LAURA ,  WEINREB PAUL H

Inventor： LEE DANIEL H S ,  WEN DINGYI ,  PEPINSKY R BLAKE ,  RELTON JANE K ,  WANG XINZHONG ,  LUGOVSKOY ALEXEY ,  MEIER WERNER ,  GARBER ELLEN A ,  SILVIAN LAURA ,  WEINREB PAUL H

IPC: A61K39/395 ,  A61K38/17 ,  C07K14/705 ,  C07K16/28 ,  C12N15/113

CPC classification number: C07K14/705 ,  A01K67/027 ,  A01K67/0275 ,  A01K2217/058 ,  A01K2227/105 ,  A01K2267/0356 ,  A61K38/179 ,  A61K39/3955 ,  A61K48/00 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/33 ,  C07K2319/74 ,  C12N15/1136 ,  C12N15/1138 ,  C12N15/8509 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Abstract translation: 公开了免疫原性Nogo受体-1多肽，Nogo受体-1抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白和编码它们的核酸。 还公开了Nogo受体拮抗剂多核苷酸。 还公开了包含这样的Nogo受体抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白，编码它们的核酸和拮抗多核苷酸的组合物以及制备和使用该组合物的方法。

公开(公告)号：WO2008086006A9

公开(公告)日：2008-09-12

申请号：PCT/US2008000316

申请日：2008-01-09

Applicant: BIOGEN IDEC INC ,  MI SHA ,  PEPINSKY R BLAKE ,  SHAO ZHAOHUI ,  GARBER ELLEN A ,  MIKLASZ STEVEN D

Inventor： MI SHA ,  PEPINSKY R BLAKE ,  SHAO ZHAOHUI ,  GARBER ELLEN A ,  MIKLASZ STEVEN D

IPC: A61K39/395

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

公开(公告)号：WO2008118356A2

公开(公告)日：2008-10-02

申请号：PCT/US2008/003735

申请日：2008-03-21

Applicant: BIOGEN IDEC MA INC. ,  UCB PHARMA S.A. ,  BURKLY, Linda C. ,  FERRANT-ORGETTAS, Janine L. ,  GARBER, Ellen A. ,  HSU, Yen-ming ,  SU, Lihe ,  TAYLOR, Frederick R. ,  ADAMS, Ralph ,  BROWN, Derek Thomas ,  POPPLEWELL, Andrew George ,  ROBINSON, Martyn Kim ,  SHOCK, Anthony ,  TYSON, Kerry Louise

Inventor： BURKLY, Linda C. ,  FERRANT-ORGETTAS, Janine L. ,  GARBER, Ellen A. ,  HSU, Yen-ming ,  SU, Lihe ,  TAYLOR, Frederick R. ,  ADAMS, Ralph ,  BROWN, Derek Thomas ,  POPPLEWELL, Andrew George ,  ROBINSON, Martyn Kim ,  SHOCK, Anthony ,  TYSON, Kerry Louise

IPC: C07K16/00

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Abstract translation: 本发明提供了特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合的，人源化的或完全人源的抗体，抗体衍生物或抗体片段，其特异性结合人源化Fab片段的表位，所述人源化Fab片段包含根据SEQ ID NO：1的可变重链序列并且包含可变轻链序列 根据SEQ ID NO：2特异性结合。 相对于第二种抗CD154抗体，本发明的CD154结合蛋白可引起降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如用于治疗和预防包括由CD154-CD40相互作用介导的不希望的免疫应答的疾病在内的疾病。

公开(公告)号：WO0025725A3

公开(公告)日：2000-11-30

申请号：PCT/US9925700

申请日：1999-11-02

Applicant: BIOGEN INC ,  WILLIAMS KEVIN ,  RAYHORN PAUL ,  GARBER ELLEN A ,  PEPINSKY BLAKE R

Inventor： WILLIAMS KEVIN ,  RAYHORN PAUL ,  GARBER ELLEN A ,  PEPINSKY BLAKE R

IPC: C12N15/09 ,  A61K38/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/46 ,  C07K14/47 ,  C07K17/08 ,  C07K17/12 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/00 ,  C12Q1/42 ,  C07K14/435 ,  C12N1/00 ,  C12N15/12

CPC classification number: C07K14/46 ,  A61K38/00 ,  C07K2319/00

Abstract: Variants of hedgehog protein that contain N-terminal modifications are described that can block hedgehog function; thus allowing these variants to serve as functional antagonists. These peptides have a primary amino acid sequence lacking the ability to elicit a hedgehog-dependent response in C3H 10T1/2 cells but having the ability to bind to the hedgehog receptor, patched-1. Methods for producing such functional antagonists and methods of using the funtional antagonists are also described.

Abstract translation: 描述了含有N端修饰的刺猬蛋白的变体，其可阻断刺猬蛋白功能; 从而允许这些变体作为功能性拮抗剂。 这些肽具有缺乏在C3H10T1 / 2细胞中引发刺猬蛋白依赖性应答但具有与hedgehog受体结合的能力的一级氨基酸序列，patched-1。 还描述了产生这种功能性拮抗剂的方法和使用功能性拮抗剂的方法。

公开(公告)号：WO9928343A9

公开(公告)日：1999-10-14

申请号：PCT/US9825676

申请日：1998-12-03

Applicant: BIOGEN INC ,  ONTOGENY INC ,  PEPINSKY R BLAKE ,  ZENG CHENHUI ,  BAKER DARREN P ,  WEN DINGYI ,  WILLIAMS KEVIN P ,  GARBER ELLEN A ,  STRAUCH KATHRYN L ,  TAYLOR FREDERICK R ,  WEINRUB PAUL H ,  PETTER RUSSELL C ,  GALDES ALPHONSE ,  PORTER JEFFREY

Inventor： PEPINSKY R BLAKE ,  ZENG CHENHUI ,  BAKER DARREN P ,  WEN DINGYI ,  WILLIAMS KEVIN P ,  GARBER ELLEN A ,  STRAUCH KATHRYN L ,  TAYLOR FREDERICK R ,  WEINRUB PAUL H ,  PETTER RUSSELL C ,  GALDES ALPHONSE ,  PORTER JEFFREY

IPC: A61K38/00 ,  A61K38/17 ,  A61K38/21 ,  A61K38/22 ,  A61K38/27 ,  A61K38/28 ,  A61P25/00 ,  A61P43/00 ,  C07K1/107 ,  C07K14/00 ,  C07K14/46 ,  C07K14/435 ,  A61K38/18

CPC classification number: A61K38/1709 ,  C07K1/1077 ,  C07K14/46 ,  C07K2319/00

Abstract: Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.

Abstract translation: 描述了疏水改性的蛋白质及其制备方法。 疏水部分与蛋白质的表面氨基酸残基连接。 疏水部分可以是脂质或肽。 或者，蛋白质可以通过将各种疏水性结构附加到蛋白质上的各种化学反应衍生化。 优选的蛋白质是哺乳动物来源的，并且选自Sonic，Indian和Desert hedgehog。 疏水性部分用作方便的绳索，可以连接囊泡如细胞膜，脂质体或胶束。

公开(公告)号：WO9928343A2

公开(公告)日：1999-06-10

申请号：PCT/US9825676

申请日：1998-12-03

Applicant: BIOGEN INC ,  ONTOGENY INC ,  PEPINSKY R BLAKE ,  ZENG CHENHUI ,  BAKER DARREN P ,  WEN DINGYI ,  WILLIAMS KEVIN P ,  GARBER ELLEN A ,  STRAUCH KATHRYN L ,  TAYLOR FREDERICK R ,  WEINRUB PAUL H ,  PETTER RUSSELL C ,  GALDES ALPHONSE ,  PORTER JEFFREY

Inventor： PEPINSKY R BLAKE ,  ZENG CHENHUI ,  BAKER DARREN P ,  WEN DINGYI ,  WILLIAMS KEVIN P ,  GARBER ELLEN A ,  STRAUCH KATHRYN L ,  TAYLOR FREDERICK R ,  WEINRUB PAUL H ,  PETTER RUSSELL C ,  GALDES ALPHONSE ,  PORTER JEFFREY

IPC: A61K38/00 ,  A61K38/17 ,  A61K38/21 ,  A61K38/22 ,  A61K38/27 ,  A61K38/28 ,  A61P25/00 ,  A61P43/00 ,  C07K1/107 ,  C07K14/00 ,  C07K14/46

CPC classification number: A61K38/1709 ,  C07K1/1077 ,  C07K14/46 ,  C07K2319/00

Abstract: Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.

Abstract translation: 描述了疏水性修饰的蛋白质及其制备方法。 疏水部分连接到蛋白质的表面氨基酸残基。 疏水部分可以是脂质或肽。 或者，蛋白质可以通过向蛋白质附加疏水结构的各种化学反应衍生化。 优选的蛋白质是哺乳动物来源的，并且选自Sonic，Indian和Desert hedgehog。 疏水部分用作方便的系链，其可以连接囊泡，例如细胞膜，脂质体或胶束。